XCUR Stock Analysis: Buy, Sell, or Hold?
XCUR - Exicure, Inc. Common Stock
$1.35
-0.01 (-0.37%)
▼
5d:
-15.94%
30d:
-29.21%
90d:
-59.85%
WAIT
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 14, 2026
4d
Get Alerted When XCUR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: XCUR is down 15.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: XCUR is down 15.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: XCUR is currently trading at $1.34, which is considered oversold relative to its 30-day fair value range of $1.54 to $1.88.
Technical Outlook: Technically, XCUR is in a strong downtrend. Immediate support is located at $1.27, while resistance sits at $1.81.
Market Sentiment: XCUR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.00 (+48.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XCUR is in a strong downtrend. Immediate support is located at $1.27, while resistance sits at $1.81.
Market Sentiment: XCUR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.00 (+48.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.54 -
$1.88
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.7% below Wall St target ($2.00)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.54 -
$1.88
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.27
Resistance Level
$1.81
Current Trend
Strong Downtrend
Technical data as of
Aug 7, 2026
Fundamental Context
Wall Street Target
$2.00
(+48.7%)
Revenue Growth (YoY)
928.0%
Share & Embed Analysis
Last updated: August 09, 2026 6:50 AM ET
Data refreshes hourly during market hours. Next update: 7:50 AM
Data refreshes hourly during market hours. Next update: 7:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XCUR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 64 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 63 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |